<DOC>
	<DOC>NCT01610037</DOC>
	<brief_summary>The study will assess the long-term safety of the fixed combination product QVA149 versus placebo and a standard of care treatment (tiotropium) in Chronic Obstructive Pulmonary Disease (COPD) patients with moderate to severe airflow limitation.</brief_summary>
	<brief_title>Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Inclusion criteria: Male and female adults aged ≥40 years. Patients with stable COPD according to GOLD strategy (GOLD 2011). Patients with airflow limitation indicated by a postbronchodilator FEV1 ≥ 30% and &lt;80% of the predicted normal, and a postbronchodilator. FEV1/FVC &lt; 0.70. Current or exsmokers who have a smoking history of at least 10 pack years. Patients with an mMRC ≥ grade 2 Exclusion criteria: History of long QT syndrome or prolonged QTc. Patients who have had a COPD exacerbation that required treatment with antibiotics and/or systemic corticosteroids and/or hospitalization in the 6 weeks prior to Visit 1. Patients with Type I or uncontrolled Type II diabetes. Patients with a history of asthma or have concomitant pulmonary disease. Patients with paroxysmal (e.g. intermittent) atrial fibrillation. Only patients with persistent atrial fibrillation and controlled with a rate control strategy for at least six months could be eligible. Patients who have clinically significant renal, cardiovascular, neurological, endocrine, immunological, psychiatric, gastrointestinal, hepatic, or hematological abnormalities which could interfere with the assessment of safety.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>QVA149</keyword>
	<keyword>QAB149</keyword>
	<keyword>NVA237</keyword>
	<keyword>Indacaterol maleate</keyword>
	<keyword>Glycopyronnium bromide</keyword>
</DOC>